Expansion of contract with biopharmaceutical company

Total contract value has increased to €1.3m

IXICO plc (AIM: IXI), the data science company delivering insights in neuroscience, today announced that it has signed a further change order to a current contract which increases the total contract value to €1.3m.
The original contract in Alzheimer’s disease was announced on 5 July 2017 and this change order reflects an extension of the contract term from September 2020 to May 2021 and the addition of new clinical sites.  The latest amendment results in a total change in the contract value of €0.5m or 65% above the original value of €0.8m.
Change orders often occur as part of the normal course of multi-year contracts, as the scope of services that IXICO provides can be expanded or extended during the term of a clinical trial.
Giulio Cerroni, Chief Executive Officer of IXICO, said:  “We are delighted to announce a further extension and expansion of this project. This change order and increase in contract value, demonstrates how closely we work with our biopharmaceutical clients to expand the services we provide to their clinical development programmes.”

PRESS RELEASE
By |2018-08-30T09:52:51+00:0030 August 2018|Contracts|